These are busy times for the folks at Oleg Nodelman’s EcoR1 Capital, an investment firm focused on therapeutic companies in the biotechnology sector.Silverback Therapeutics, a clinical-stage biopharmaceutical company backed by EcoR1 Capital, filed plans with regulators this week to go public. On the same